Home › Funds › PGGM Investments › REGN
PGGM Investments position in REGN
REGENERON PHARMACEUTICALS · Health Care
PGGM Investments reported holding 25,588 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$19.4M, representing 0.48% of its reported portfolio and ranking #50 among its reported holdings. PGGM Investments has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How PGGM Investments's REGN position evolved
PGGM Investments first disclosed a stake in REGN in Q3 2023 at 56,642 shares (US$46.6M). The position peaked in Q1 2026 at 92,584 shares, worth US$71.5M. Across 13 filings, PGGM Investments increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 25,588 shares valued at US$19.4M — a reduction of -66,996 shares quarter over quarter.. Notable position changes include a 36% trim in Q4 2023 (shares rose 10% over the following quarter), a 160% increase in Q2 2025 (shares rose 8% over the following quarter), a 72% trim in Q3 2026 (shares rose 26% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 56.64K | $46.61M | New |
| Q4 2023 | 36.03K | $31.64M | Reduce |
| Q1 2024 | 36.03K | $34.68M | Hold |
| Q2 2024 | 32.73K | $34.40M | Reduce |
| Q3 2024 | 26.20K | $27.54M | Reduce |
| Q4 2024 | 32.50K | $23.15M | Add |
| Q1 2025 | 32.50K | $20.61M | Hold |
| Q2 2025 | 84.40K | $44.31M | Add |
| Q3 2025 | 92.58K | $52.06M | Add |
| Q4 2025 | 92.58K | $71.46M | Hold |
| Q1 2026 | 92.58K | $71.53M | Hold |
| Q2 2026 | 92.58K | $57.73M | Hold |
| Q3 2026 | 25.59K | $19.40M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Franklin Resources 2.95M sh · $2.75B · Q3 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
- LOOMIS SAYLES & CO L P 1.72M sh · $1.30B · Q3 2026
More on PGGM Investments
FAQ
How long has PGGM Investments held REGN?
PGGM Investments has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is PGGM Investments's current position in REGN?
As of Q3 2026, PGGM Investments holds 25.59K shares of REGN (REGENERON PHARMACEUTICALS), valued at $19.40M, representing 0.48% of its reported portfolio and ranking #50.
Has PGGM Investments been buying or selling REGN?
In the latest 13F filing (Q3 2026), PGGM Investments reduced its position in REGN. The position peaked in Q1 2026 at 92.58K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.